TJPC(600488)2025-03-26 11:45Financial Performance - In 2023, net profit increased by 230.60% year-on-year, with further performance improvement expected in 2024[6]. - The company's operating revenue for 2024 was CNY 3,215,285,232.59, a decrease of 15.00% compared to CNY 3,782,826,621.15 in 2023[31]. - Net profit attributable to shareholders for 2024 was CNY 133,450,642.68, an increase of 14.01% from CNY 117,052,520.50 in 2023[31]. - The net cash flow from operating activities decreased by 27.28% to CNY 569,371,797.90 in 2024 from CNY 783,008,315.33 in 2023[31]. - The total assets as of the end of 2024 were CNY 5,698,286,373.15, a decrease of 7.23% from CNY 6,142,482,199.13 at the end of 2023[31]. - Basic earnings per share for 2024 increased to CNY 0.122, up 14.02% from CNY 0.107 in 2023[32]. - The weighted average return on net assets for 2024 was 4.45%, an increase of 0.50 percentage points from 3.95% in 2023[32]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 136,288,020.42, a 27.11% increase from CNY 107,223,594.29 in 2023[31]. - The net assets attributable to shareholders at the end of 2024 were CNY 3,057,347,087.18, an increase of 3.51% from CNY 2,953,554,191.30 at the end of 2023[31]. Market Presence and Expansion - The company has 60% of its steroid hormone raw materials exported to over 70 countries and regions across Asia, Europe, and America, with domestic sales covering nearly 100 cities[8]. - The company plans to continue expanding its overseas market presence and has received GMP certification for several products in Brazil and the USA[8]. - The company is committed to becoming a leader in emergency and cold standby drugs, ensuring drug safety and accessibility[9]. - The company is actively responding to new safety production regulations, improving its safety management system, and investing in automation upgrades and dual prevention systems[56]. - The company is focusing on developing new products in the emergency medication sector, including a range of injectable solutions[156]. Research and Development - Five products have received drug registration certificates from the National Medical Products Administration in 2024, and ten products have passed the consistency evaluation of generic drug quality and efficacy[9]. - R&D investment for 2024 reached 248 million RMB, accounting for 7.7% of total operating revenue[44]. - The company applied for 18 patents and received 18 patent authorizations during the reporting period, indicating a strong focus on innovation and product development[65]. - The company is conducting ongoing research and development on various new products, including amino acid drugs and broad-spectrum antibiotics, with several in different stages of approval[112]. - The company has a pipeline of new drug applications, including XP0021, which is under review for severe allergic conditions and acute rejection reactions[116]. Operational Efficiency and Management - The company aims to enhance operational efficiency by compressing management levels and optimizing resource allocation[6]. - The company has implemented various cost reduction strategies, resulting in a 13.45% decrease in operating costs[74]. - Sales expenses decreased by 45.76% due to improved management and optimized sales models[74]. - The company has strengthened internal management through lean production and process optimization, aiming to reduce costs and improve efficiency[62]. - The company has implemented a new CRM system to enhance operational sales management capabilities[43]. Compliance and Governance - The company will focus on compliance and internal control to support sustainable development in the face of evolving market challenges[10]. - The company has established a compliance management system to enhance its ability to identify and manage compliance risks[48]. - The company achieved a 100% compliance rate in information disclosure, with zero errors in 2024[174]. - The company maintained a sound corporate governance structure with independent organizational entities, ensuring compliance with laws and regulations[177]. Awards and Recognition - The company has been recognized in the top 100 of the 2024 China Drug R&D Comprehensive Strength Ranking and the 2024 China Chemical Drug R&D Strength Ranking[9]. - The company received 8 awards for quality management at national and municipal levels in 2024[45]. - The company was recognized in the "2024 China Pharmaceutical R&D Comprehensive Strength Ranking" and the "2024 China Chemical Pharmaceutical R&D Strength Ranking" as part of the top 100[49]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies in the upcoming year[22]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies in the biopharmaceutical sector[101]. - The company is enhancing its digital marketing efforts, with an investment of 50 million yuan to increase brand visibility[101]. - The company is actively pursuing mergers and acquisitions to enhance its portfolio and market share in the pharmaceutical industry[130]. Financial Management - The company achieved a cash dividend distribution ratio of 80.18% for the year, amounting to a total cash dividend of approximately 107 million yuan[15]. - The company has a high cash dividend ratio of 81.31%, distributing 0.87 yuan per 10 shares to shareholders[175]. - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 804.12 million yuan[180].